DAVID DESAI: Open Payments
NPI 1740451566 · REDLANDS, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$6,479 in 322 payments from 21 companies in 2025. Trend: 2023 $4,626 · 2024 $4,133 · 2025 $6,479
Food & beverage: $6,473Education: $5
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 41 | $1,053 |
| Otsuka America Pharmaceutical, Inc. | 47 | $1,020 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 35 | $645 |
| Janssen Pharmaceuticals, Inc | 31 | $636 |
| Teva Pharmaceuticals USA, Inc. | 26 | $533 |
| ABBVIE INC. | 33 | $525 |
| Axsome Therapeutics, Inc. | 18 | $406 |
| Lundbeck LLC | 16 | $369 |
| Alkermes, Inc. | 12 | $270 |
| Vanda Pharmaceuticals Inc. | 16 | $257 |
Products named: REXULTI, INGREZZA, CAPLYTA, VRAYLAR, Auvelity, AUSTEDO XR, SPRAVATO, INVEGA SUSTENNA.
Industry payments across CA — which companies pay providers there.
